Discovering the true signals of disease to power life-changing drugs.
Company is active
Event Year: 2019
Company is active
Event Year: 2019
The pharmaceutical industry faces a significant challenge: approximately 90% of drug candidates ultimately fail during development. This high failure rate not only represents a substantial financial burden but also delays the availability of potentially life-saving treatments for patients in need. Sequence Bio is dedicated to addressing this critical issue. Their mission is to revolutionize drug target discovery by leveraging the unique genetic characteristics of the Newfoundland founder population, aiming to identify more effective and promising drug targets and ultimately accelerate the development of life-changing medications.
The pharmaceutical industry faces a significant challenge: approximately 90% of drug candidates ultimately fail during development. This high failure rate not only represents a substantial financial burden but also delays the availability of potentially life-saving treatments for patients in need. Sequence Bio is dedicated to addressing this critical issue. Their mission is to revolutionize drug target discovery by leveraging the unique genetic characteristics of the Newfoundland founder population, aiming to identify more effective and promising drug targets and ultimately accelerate the development of life-changing medications.
Total Raised: Unknown (Y Combinator backed)
Last Round: Summer 2019
Total Raised: Unknown (Y Combinator backed)
Last Round: Summer 2019
Healthcare
Healthcare
Healthcare -> Drug Discovery and Delivery
Healthcare -> Drug Discovery and Delivery
Team size: 52
Hiring: No
Team size: 52
Hiring: No
